Inhibitors are antibodies directed against haemophilia treatment products which interfere
with their function. Factor VIII (FVIII) inhibitors in haemophilia A and factor IX (FIX) inhibitors …

Factor VIII (FVIII) is an important component of blood coagulation as its congenital deficiency
results in life-threatening bleeding. Current prophylactic therapy of the disease (hemophilia …

Gene therapy for hemophilia A would be facilitated by development of smaller expression
cassettes encoding factor VIII (FVIII), which demonstrate improved biosynthesis and/or …

INTRODUCTION: Host cell lines used for recombinant protein expression differ in their
ability to perform post-translational modifications (PTMs). The currently available …

Hemophilia A is the X-linked bleeding disorder caused by deficiency of coagulation factor
VIII (FVIII). To address serious complications of inhibitory antibody formation in current …

Introduction Since the early 1990s, recombinant human clotting factor VIII (rhFVIII) produced
in hamster cells has been available for haemophilia A treatment. However, the post …

Background Factor VIII (FVIII) and von Willebrand factor (VWF) circulate in plasma in a tight
non-covalent complex, being critical to hemostasis. Although structurally unrelated, both …

The gut associated lymphoid tissue has effective mechanisms in place to maintain tolerance
to food antigens. These can be exploited to induce antigen-specific tolerance for the …

Hemophilia A (HA) and hemophilia B (HB) are X-linked bleeding disorders due to
inheritable deficiencies in either coagulation factor VIII (FVIII) or factor IX (FIX), respectively …

Gene-based therapy opens an entirely new paradigm in managing people with haemophilia
(PWH), offering them the possibility of a functional cure by enabling continuous expression …